Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic

 

Show simple item record

dc.contributor.advisor Parker, Romy
dc.contributor.author Moabelo, Machuene
dc.date.accessioned 2021-02-11T16:33:57Z
dc.date.available 2021-02-11T16:33:57Z
dc.date.issued 2020
dc.identifier.citation Moabelo, M. 2020. Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic. . ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine. http://hdl.handle.net/11427/32816 en_ZA
dc.identifier.uri http://hdl.handle.net/11427/32816
dc.description.abstract Background Neuropathic pain (NP), defined as pain caused by a lesion or disease of the somatosensory system, affects 6.9 – 10 % of people worldwide. Pregabalin is currently recommended as a first line drug for NP in South Africa. Methods A cross-sectional retrospective descriptive medicines usage evaluation (MUE) of Pregabalin at Groote Schuur Chronic Pain clinic for the year 2017 was conducted. A MUE using a standardized data collection form was performed on 100 randomly selected folders. Data are summarized using descriptive statistics. Results The majority of cases were women (76) with a mean age of 55.9y (SD12.49). A diagnosis of NP was recorded in 58 folders and a “possible” diagnosis recorded in 7 folders. In 79 cases there was no mention of a tool/method used to diagnose NP. The most common condition diagnosed was chronic post-surgical pain with a neuropathic component (n=16), followed by NP (n=15). The most common initiating and current dose of Pregabalin was 75mg twice daily. In 56 patients, Pregabalin was prescribed in conjunction with a tricyclic antidepressant (TCA) or selective noradrenaline reuptake inhibitor (SNRI). Patient education was documented as having taken place in 76 of cases. Conclusions Based on this MUE we recommend the use of screening tools for the diagnosis of neuropathic pain, and a focus on the initiating dose of Pregabalin. The use of a standardized assessment document and the interdisciplinary team input at this clinic appears to optimize prescribing of Pregabalin in line with practice guidelines.
dc.subject Neuropathic pain
dc.subject Pregabalin
dc.subject medicines usage evaluation
dc.subject Groote Schuur Chronic Pain clinic
dc.title Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic
dc.type Master Thesis
dc.date.updated 2021-02-11T16:23:11Z
dc.language.rfc3066 eng
dc.publisher.faculty Faculty of Health Sciences
dc.publisher.department Department of Anaesthesia and Perioperative Medicine
dc.type.qualificationlevel Masters
dc.type.qualificationlevel MMed
dc.identifier.apacitation Moabelo, M. (2020). <i>Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic</i>. (). ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine. Retrieved from http://hdl.handle.net/11427/32816 en_ZA
dc.identifier.chicagocitation Moabelo, Machuene. <i>"Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic."</i> ., ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine, 2020. http://hdl.handle.net/11427/32816 en_ZA
dc.identifier.vancouvercitation Moabelo M. Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic. []. ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine, 2020 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/32816 en_ZA
dc.identifier.ris TY - Master Thesis AU - Moabelo, Machuene AB - Background Neuropathic pain (NP), defined as pain caused by a lesion or disease of the somatosensory system, affects 6.9 – 10 % of people worldwide. Pregabalin is currently recommended as a first line drug for NP in South Africa. Methods A cross-sectional retrospective descriptive medicines usage evaluation (MUE) of Pregabalin at Groote Schuur Chronic Pain clinic for the year 2017 was conducted. A MUE using a standardized data collection form was performed on 100 randomly selected folders. Data are summarized using descriptive statistics. Results The majority of cases were women (76) with a mean age of 55.9y (SD12.49). A diagnosis of NP was recorded in 58 folders and a “possible” diagnosis recorded in 7 folders. In 79 cases there was no mention of a tool/method used to diagnose NP. The most common condition diagnosed was chronic post-surgical pain with a neuropathic component (n=16), followed by NP (n=15). The most common initiating and current dose of Pregabalin was 75mg twice daily. In 56 patients, Pregabalin was prescribed in conjunction with a tricyclic antidepressant (TCA) or selective noradrenaline reuptake inhibitor (SNRI). Patient education was documented as having taken place in 76 of cases. Conclusions Based on this MUE we recommend the use of screening tools for the diagnosis of neuropathic pain, and a focus on the initiating dose of Pregabalin. The use of a standardized assessment document and the interdisciplinary team input at this clinic appears to optimize prescribing of Pregabalin in line with practice guidelines. DA - 2020 DB - OpenUCT DP - University of Cape Town KW - Neuropathic pain KW - Pregabalin KW - medicines usage evaluation KW - Groote Schuur Chronic Pain clinic LK - https://open.uct.ac.za PY - 2020 T1 - Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic TI - Gabapentinoids for treatment of neuropathic pain: a medicines usage evaluation at the Groote Schuur hospital chronic pain management clinic UR - http://hdl.handle.net/11427/32816 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record